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In phenylketonuria (PKU) patients, early diagnosis by neonatal screening and immediate 
institution of a phenylalanine-restricted diet can prevent severe intellectual impairment. 
Nevertheless, outcome remains suboptimal in some patients asking for additional 
treatment strategies. Tetrahydrobiopterin (BH4) could be one of those treatment options, 
as it may not only increase residual phenylalanine hydroxylase activity in BH4-responsive 
PKU patients, but possibly also directly improves neurocognitive functioning in both 
BH4-responsive and BH4-unresponsive PKU patients. In the present review, we aim to 
further define the theoretical working mechanisms by which BH4 might directly influence 
neurocognitive functioning in PKU having passed the blood-brain barrier. Further 
research should investigate which of these mechanisms are actually involved, and should 
contribute to the development of an optimal BH4 treatment regimen to directly improve 
neurocognitive functioning in PKU. Such possible repurposing approach of BH4 
treatment in PKU may improve neuropsychological outcome and mental health in both 
BH4-responsive and BH4-unresponsive PKU patients. 
 
Take-home message: 
Tetrahydrobiopterin may directly improve neurocognitive functioning in phenylketonuria 
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Given its success, treatment of phenylketonuria (PKU; OMIM 261600) has classically 
focused on controlling blood phenylalanine (Phe) concentrations to prevent irreversible 
intellectual disability. This is mainly done by institution of a Phe-restricted diet following 
a positive neonatal screening test for PKU (Blau et al 2010). Additionally, 20-50% of 
PKU patients benefit from chaperone activity of tetrahydrobiopterin (BH4) for the Phe 
hydroxylase enzyme (PAH; EC 1.14.16.1) (Keil et al 2013). In these so-called BH4-
responsive patients, pharmacological treatment with BH4 results in increased PAH 
activity, leading to a decrease in blood Phe concentrations and/or an increase in natural 
protein tolerance. Notwithstanding the effects of the Phe-restricted diet and/or BH4 
treatment to prevent severe intellectual disability, some early-treated PKU patients still 
show mild impairments in executive and social-cognitive functioning and social skills, 
and are prone to develop anxiety and depressive symptoms (Smith and Knowles 2000, 
Jahja et al 2014, Jahja et al 2016). These findings have often been attributed to Phe 
neurotoxicity and cerebral neurotransmitter impairments (Dyer 1999, Christ et al 2010). 
Interestingly, anecdotally, some BH4-unresponsive PKU patients experience a better 
ability to concentrate and less behavioural problems on BH4 supplementation during the 
short periods of time when being tested for BH4-responsiveness, despite not showing a 
decrease in blood Phe concentrations (Cederbaum 2011). Although these reports may 
simply indicate placebo effects, it raises the question whether BH4 could directly improve 
neurocognitive and psychosocial functioning beyond its effect of reducing blood Phe 
concentrations in BH4-responsive PKU patients. This hypothesis is further substantiated 
by a pilot study in late-diagnosed PKU patients with maladaptive behaviour, of whom 
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most were BH4-unresponsive, showing improved behaviour after 1 year of BH4 treatment 
(20 mg/kg/day) (Moseley et al 2015). Thereby, if BH4 will indeed be shown to directly 
improve neurocognitive functioning beyond its effect on the PAH enzyme, such a 
repurposing approach may extend the target population of BH4 treatment. 
Different working mechanisms, substantiated by different levels of evidence, may 
underlie such a possible direct beneficial effect of BH4 on neurocognitive functioning in 
PKU patients as summarized in Figure 1 and Table 1. In the present review, we aim to 
further define these theoretical working mechanisms in order to stimulate further research 
on the possible neurocognitive effects of BH4 to ultimately be able to use BH4 in PKU 
patients to its full potential. 
 
BH4 and the brain 
Before discussing several mechanisms through which BH4 could directly improve 
neurocognitive functioning, this review will focus on the question to what degree BH4 
supplementation can increase cerebral BH4 concentrations. It is known that orally 
administered BH4 is largely rapidly excreted through feces and urine, the latter being 
facilitated by high-capacity organic anion transporters in the kidney (Ohashi et al 2012, 
Ohashi et al 2017). BH4 furthermore shows slow transport across cell membranes, 
compared to related pterins such as sapropterin and dihydrobiopterin (BH2) (Ohashi et al 
2017). Next to this, BH4 is an instable molecule that is easily oxidized to BH2, although it 
appears BH2 is then intracellularly reconverted into BH4 (Ohashi et al 2016). Overall, 
BH4 supplementation does increase plasma BH4 concentrations (Zurflüh et al 2006), 
albeit very inefficiently, but it is unclear to what extent BH4 then crosses the blood-brain 
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barrier (BBB). At least in part, this question is prompted by the experience of BH4 
treatment in patients with BH4 deficiency, resulting in a disturbed function of PAH, as 
well as of tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH). Patients with 
BH4 deficiency due to for example a defect in dihydropteridine reductase only benefit 
from BH4 treatment with regard to liver Phe metabolism, and not with regard to cerebral 
TH and TPH activity (Ponzone et al 2004), suggesting BH4 does not reach the brain. This 
similarly applies to patients with BH4 deficiency as a result of 6-pyruvoyl 
tetrahydropterin synthase deficiency (Porta et al 2009). While this seems to contrast with 
the previously mentioned reports of direct neurocognitive effects of BH4 in PKU patients, 
these discrepancies could be explained by a difference in BH4 dosage. Namely, the dose 
of BH4 in responsiveness testing and treatment in PKU can be much higher (up to 20 
mg/kg body weight) compared to the dose of BH4 in the treatment of BH4 defects 
(usually below 10 mg/kg body weight). It has indeed been shown that BH4 could pass the 
BBB and increase cerebral BH4 in a dose-dependent manner in mice (Thony et al 2008). 
Moreover, some studies suggest that BH4 could also reach the brain in humans. BH4 
administration (20 mg/kg/day) in children with autism spectrum disorder has also been 
shown to improve social awareness, autism mannerisms, hyperactivity, and inappropriate 
speech (Klaiman et al 2013). High doses of BH4 are probably necessary to cross the BBB, 
as shown by increased biopterin concentrations in cerebrospinal fluid (CSF) in humans 
and rhesus monkeys following BH4 administration at 20 mg/kg or higher (al Aqeel et al 
1992, Ishida et al 1988, Kaufman et al 1982, Miller et al 1986), but not at lower doses (al 
Aqeel et al 1992). Overall, while some studies indicate that BH4 supplementation may 
increase cerebral BH4 concentrations, it is important to emphasize that the extent to which 
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this happens is not yet clear and this essential question requires further research. Higher 
dosages of BH4 than currently used may be necessary to establish an increase in cerebral 
BH4 that could result in relevant therapeutic effects. Alternatively, the use of sepiapterin, 
which is a precursor of BH4, may be considered for this purpose. Although the exact 
mechanism has not yet been elucidated, it has been shown that administration of 
sepiapterin is more effective in increasing intracellular BH4 concentrations compared to 
administration of BH4 directly, with the latter resulting in a larger increase in intracellular 
BH2 concentrations (Hasegawa et al 2005). Moreover, a very recent clinical trial showed 
that administration of a therapeutic formula of sepiapterin was well-tolerated in healthy 
subjects, and increased plasma BH4 concentrations more efficiently compared to BH4 





Some reports have warranted against the indiscriminate use of high-dose BH4 treatment 
because of possible toxicity. In one study in BH4-deficient mice, acute subcutaneous 
BH4 administration at 300 mg/kg resulted in the death of 2 of 12 animals (Brand et al 
1996), which has been suggested to be related to nonspecific stimulation of NO 
synthesis (Brand et al 1996, Klatt et al 1992). Such apparent toxicity, however, has not 
been observed in mice at subcutaneous administration of lower doses (30 or 90 mg/kg) 
(Brand et al 1996) or at subchronic oral administration up to 100 mg/kg (Thony et al 
2008, Brand et al 1996) or acute oral administration up to 1300 mg/kg (Lewandowski, 
Combs and Folkers 1986). For subchronic intraperitoneal BH4 administration in mice, 
the median lethal dose has been found to be 260 mg/kg (Lewandowski et al 1986). In 
PKU patients, BH4 treatment (up to 20 mg/kg/day) is considered safe, with a low rate 
of adverse effects (Longo et al 2015). 
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BH4 and monoaminergic neurotransmitter synthesis 
As a first hypothetical working mechanism by which BH4 may directly improve 
neurcognitive functioning in PKU patients, BH4 is suggested to increase cerebral 
monoaminergic neurotransmitter synthesis. Cerebral monoaminergic neurotransmitter 
deficiencies are considered an important pathophysiological factor underlying brain 
dysfunction in PKU (Surtees and Blau 2000), resulting from insufficient brain uptake of 
their amino acid precursors (tyrosine (Tyr) and tryptophan (Trp)) and/or inhibition of TH 
and TPH – the enzymes being responsible for the rate limiting steps in dopaminergic and 
serotonergic neurotransmitter synthesis – by elevated brain Phe concentrations (de Groot 
et al 2010). In both living and deceased PKU patients, decreased Tyr and Trp levels in 
brain as well as reduced dopaminergic and serotonergic metabolites in CSF have been 
reported (Burlina et al 2000, McKean 1972). Moreover, a reduction in TH protein 
expression of 40% in medial prefrontal cortex of the BTBR Pah-enu2 PKU mouse model 
has been observed (Pascucci et al 2012). No such reductions have been found for cerebral 
protein expression of TPH in this PKU mouse model, although enzyme activity levels 
were shown to be significantly reduced (Pascucci et al 2009). 
BH4 may directly stimulate cerebral monoaminergic synthesis in PKU patients, although 
the catecholaminergic and serotonergic system might respond differently to BH4 
administration. This hypothesis is substantiated by various findings. Firstly, with regard 
to the catecholaminergic system, TH activity and protein expression significantly 
increased in wild-type mice following oral BH4 administration (20 and 100 mg/kg) 
(Thony et al 2008). Also, in BH4 knock-out mice, chronic intraperitoneal BH4 
administration (50 mg/kg) improved TH activity, thereby increasing brain dopamine 
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concentrations (Sumi-Ichinose et al 2001), and the reduction of TH protein expression in 
striatum was partly reversed by BH4 administration (50 mg/kg) (Sumi-Ichinose et al 
2001, Homma et al 2013). Additionally, as observed by in vivo microdialysis, dopamine 
concentrations increased on BH4 infusion in striatum of healthy rats, and this effect was 
further enhanced by continuous infusion of Tyr at a relatively low dose (Tsukada et al 
1994). Secondly, with regard to the serotonergic system, acute BH4 administration in BH4 
knock-out mice strongly increased brain serotonin concentrations without any effect on 
TPH activity (Sumi-Ichinose et al 2001). In line with that study, BH4 treatment (50 
mg/kg/day) in Pah-enu1/2 mice led to a partial recovery of brain serotonin levels, but 
again without increased TPH activity (Scherer et al 2018).  
Nevertheless, the effects of BH4 administration in mice and rats are somewhat 
inconclusive, with BH4 administration (20, 40 and 100 mg/kg) in one study not resulting 
in changed dopamine and serotonin concentrations in wild-type mice (Thony et al 2008), 
while other studies, in wild-type rats and BH4 knock-out mice, respectively, showed 
increased biosynthesis of both monoaminergic neurotransmitters (Miwa, Watanabe and 
Hayaishi 1985, Brand et al 1996), although this effect was only achieved at toxic dose 
(300 mg/kg) in one of these studies (Brand et al 1996) 
More recently, blood and urine melatonin and urine dopamine concentrations, that are 
thought to reflect brain serotonin and dopamine availability in the CNS, were found to be 
not changed by BH4 administration in BH4-responsive and BH4-unresponsive patients 
(Yano et al 2016). On the other hand, observations in BH4-responsive PKU patients 
suggested a direct positive effect of BH4 on cerebral dopamine bio-availability beyond its 
effect through lowering blood Phe concentrations (van Vliet et al 2015). In this study, in 
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male BH4-responsive PKU patients, blood prolactin concentrations – as a peripheral 
parameter to reflect cerebral dopamine concentrations – were found to be significantly 
lower on BH4 treatment if compared to treatment without BH4, even when correcting for 
blood Phe concentrations, and tended to be lower at increasing BH4 dose. It is important 
to emphasize, however, that both studies assessed indirect measures of brain 
monoaminergic neurotransmitters. 
Overall, while reports are still inconclusive, studies in PKU mice and patients suggest a 
benefit of BH4 treatment to directly improve brain monoaminergic neurotransmitter 
synthesis in PKU (Table 1), which consequently might lead to improved neurotransmitter 
release and neurotransmission. The different responses of the catecholaminergic and 
serotonergic system, as well as the possible beneficial effects on neurocognitive 
functioning in PKU patients, certainly warrant further investigations. 
 
BH4 and neuronal monoaminergic neurotransmitter release 
Besides stimulating monoaminergic neurotransmitter synthesis, BH4 in PKU patients may 
also improve neurocognitive functioning by increasing neuronal dopamine and serotonin 
release either directly or through stimulation of NO production. Neuronal release of 
monoaminergic neurotransmitters has not been investigated in PKU patients, but research 
in the PKU mouse model has shown clear impairments in neuronal monoamine release 
(Pascucci et al 2009, Pascucci et al 2012). Although impaired neuronal monoaminergic 
neurotransmitter release in PKU could partly be explained by insufficient 
neurotransmitter synthesis, this may not be the only underlying mechanism. Firstly, 
disturbed NO metabolism in PKU might contribute to the observed impairments in 
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neuronal monoaminergic neurotransmitter release. Disturbed NO metabolism was 
reported in both PKU patients (Huemer et al 2012, Okano and Nagasaka 2013, Sanayama 
et al 2011) and in PKU mouse brain (Embury, Reep and Laipis 2005), and is 
hypothesized to result from increased oxidative stress. Cerebral NO is involved in both 
synaptic and nonsynaptic neurotransmission. As such, impaired cerebral NO metabolism 
in PKU can be suggested to contribute to dysfunctional monoaminergic 
neurotransmission. Secondly, alterations in neuronal Ca2+ channels have been reported in 
cell studies, which may be related to impaired neuronal monoamine release in PKU 
(Dzhura et al 1998, Zhang and Gu 2005). These alterations in Ca2+ channels are 
hypothesized to result from the disturbed amino acid balance in the PKU brain (Dzhura et 
al 1998, Kostyuk, Martynyuk and Pogorelaya 1991, Martynyuk, Savina and Skibo 1991).  
Several studies, although mostly not related to PKU, suggest that BH4 has an effect on 
monoaminergic neurotransmitter synthesis. In vivo microdialysis with intracerebral BH4 
infusion was found to increase neuronal dopamine and serotonin release in a dose-
dependent manner in striatum from healthy rats (Koshimura et al 1990, Koshimura, Miwa 
and Watanabe 1994, Koshimura et al 1995, Mataga, Imamura and Watanabe 1991, Wolf 
et al 1991). For dopamine, a similar effect of BH4 has been observed in rat frontal cortex 
(Mataga et al 1991). Furthermore, a more recent study showed increased metabolism of 
serotonin and dopamine in PKU mice despite unaltered concentrations of these 
neurotransmitters, which might be explained by an increase in synaptic monoaminergic 
neurotransmitter release (Winn et al 2016).  
This effect of BH4 may be exerted by two different mechanisms that are theoretically 
related to the causes of impaired neuronal monoaminergic neurotransmitter release in 
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PKU. Firstly, BH4 is (together with flavin adenine dinucleotide and flavin 
mononucleotide) one of the essential cofactors for NOS, catalyzing the conversion of 
arginine into NO and citrulline, also in the brain. Research in both rats and mice indeed 
suggest an increase in cerebral NO production by NOS following BH4 administration 
(Fabian, Perez-Polo and Kent 2008, Koshimura et al 2004). Extensive research, as 
reviewed by Kiss (2000), has shown that NO influences neuronal release of 
monoaminergic neurotransmitters (Kiss 2000). Although controversy exists concerning 
the exact role of NO in monoaminergic neurotransmission, the majority of data has 
indicated that NO stimulates dopaminergic, noradrenergic, and serotonergic neuronal 
release (Kiss 2000). Secondly, besides acting through NO, BH4 has also been shown to 
directly enhance neuronal dopamine and serotonin release (Koshimura et al 1990, 
Koshimura et al 1994, Wolf et al 1991, Koshimura et al 2000, Koshimura et al 1992) 
independent of its cofactor activity. Such effect would be mediated by activation of Ca2+ 
channels (Wolf et al 1991, Koshimura et al 2000, Shiraki et al 1996) via the cAMP 
protein kinase A pathway (Koshimura et al 2000). 
To conclude, the possible effect of BH4 treatment on neuronal monoaminergic 
neurotransmitter release and thereby neurotransmission has only been investigated in 
animal studies, mostly not related to PKU (Table 1). However, given the similarities in 
the possible mechanisms underlying impaired monoaminergic neurotransmission in PKU 
and the modes of action of BH4, this might well offer a potentially useful therapeutic 




BH4 and glutamatergic synaptic transmission 
Although most research has focused on the possible effect of BH4 on synthesis and 
neuronal release of monoaminergic neurotransmitters, BH4 could also improve 
glutamatergic neurotransmission. Glutamate is the primary excitatory neurotransmitter in 
the brain, and has been shown to regulate neurogenesis, neurite outgrowth, 
synaptogenesis, and neuronal survival (Mattson 2008). As such, glutamatergic synaptic 
transmission is crucial for normal brain functioning, and impaired glutamatergic synaptic 
transmission has been associated with a diverse group of neurological disorders (Mattson 
2008). Also in PKU, impaired glutamatergic synaptic transmission has been hypothesized 
to contribute to brain dysfunction (Martynyuk et al 2005). Both in vitro and in vivo 
studies in rats and PKU mice have shown that high Phe concentrations impair 
glutamatergic synaptic transmission through both presynaptic and postsynaptic effects 
(Glushakov et al 2002, Glushakov et al 2003, Glushakov et al 2005). This mechanism has 
been suggested to be responsible for impaired learning and memory in PKU mice 
(Glushakov et al 2005), and has been associated with susceptibility of BTBR Pah-enu2 
mice to audiogenic seizures (Martynyuk et al 2007). 
As BH4 has been found to induce neuronal glutamate release in striatum and frontal 
cortex from healthy rats (Mataga et al 1991), BH4 might improve glutamatergic synaptic 
transmission in PKU and thereby improve neuropsychological functioning. The exact 
mechanism by which BH4 would stimulate neuronal glutamate release has not been fully 
elucidated yet. The finding that increased glutamatergic neuronal release on BH4 
treatment was abolished by concomitant administration of 6-hydroxydopamine, 
destroying the dopaminergic nerve terminals, may suggest that the possible effect of BH4 
 15
on striatal glutamate release is mediated by proper functioning dopaminergic neurons 
(Mataga et al 1991). Alternatively, it can be hypothesized that the effect of BH4 is 
mediated by increased NO production, as NO has also been found to stimulate neuronal 
glutamate release (Neitz et al 2011). Overall, this hypothesis is mostly based on a single 
animal study not related to PKU (Table 1). Therefore, whether BH4 treatment could 
stimulate glutamatergic synaptic transmission in PKU and thereby improve 
neurocognitive functioning still remains to be established. 
 
BH4 and oxidative stress 
Theoretically, BH4 may improve neurocognitive functioning in PKU patients by 
protecting against oxidative stress. Oxidative stress is defined as an imbalance between 
free radicals and antioxidant defense systems and is usually followed by oxidative cell 
injury and death. Research on this subject in PKU patients and mice, as reviewed by 
Ribas et al. (2011), suggests that oxidative stress could be an import mechanism leading 
to brain damage in PKU as a result of both increased reactive species production and 
decreased antioxidant defenses (Ribas et al 2011).  
In oxidative stress, BH4 plays a vital anti-oxidative role as a result of its interplay with 
nitric oxide synthase (NOS) (Thöny, Auerbach and Blau 2000, Schulz et al 2008). During 
oxidative stress, NOS generates superoxide, which is a reactive oxygen species, thereby 
further aggravating the oxidative situation. BH4 is able to prevent the formation of 
superoxide by interacting with NOS, which is called ‘NOS coupling’. However, 
especially during oxidative stress, BH4 is oxidized to BH2 leading to ‘NOS uncoupling’, 
thereby no longer protecting against free radicals. In case of oxidative stress, as observed 
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in PKU, a high intracellular BH4 level might therefore be critical to maintain 
homeostasis, so that increased BH4 availability in the brain might lead to a better 
protection against oxidative damage. However, it should be noted that the extent to which 
peripherally administered BH4 could protect against oxidative stress largely depends on 
the increase of BH4 concentrations relative to that of BH2, e.g. the BH2/BH4 ratio, as 
studies in endothelial cells in vitro and in healthy rats indicate that an increase in this 
ratio would actually result in more oxidative stress (Crabtree et al 2008, Noguchi et al 
2011). Thus, while BH4 itself may decrease oxidative stress, BH4 treatment may 
ultimately lead to too high BH2 levels and by this may increase oxidative stress. 
Therefore, this possible negative effect of BH4 treatment should be kept in mind and may 
be very relevant when considering the hypothesized benefits of BH4 treatment in general. 
The effect of BH4 on oxidative stress has been investigated in research areas other than 
PKU. Some studies focusing on the vascular system, performed in both humans an mice, 
indeed suggest that BH4 decreases oxidative stress (Cosentino et al 2008, Santhanam, 
d'Uscio and Katusic 2014), while other human studies show no effects of BH4 on the 
cardiovascular system, possibly due to increased BH2 levels (Cunnington et al 2012, 
Reverter et al 2015). Overall, BH4 may in theory have positive effects on neurocognitive 
functioning of PKU patients by decreasing oxidative stress, but the effect of BH4 on 
oxidative stress in the PKU brain has not yet been examined. Meanwhile, the possible 





BH4 and cerebral energy metabolism 
BH4 might also have a positive effect on the brain by improving cerebral glucose 
metabolism through increased cerebral blood flow. Impaired cerebral energy status has 
been observed in both PKU patients (Hasselbalch et al 1996, Pietz et al 2003, 
Wasserstein et al 2006, Ficicioglu et al 2013) and PKU mice (Qin and Smith 2007). The 
role of such impaired cerebral energy metabolism on brain functioning in PKU is 
however largely unknown. Reduced cerebral energy metabolism has been suggested to 
relate to white matter abnormalities in PKU (Hasselbalch et al 1996), while increased 
cerebral glucose metabolism, which has been observed in particular brain areas in PKU 
patients (Ficicioglu et al 2013, Wasserstein et al 2006), has been suggested to reflect 
some compensatory mechanism (Ficicioglu et al 2013). 
The effect of BH4 (at 20 mg/kg/day) on brain glucose metabolism as measured by FDG-
PET has been investigated in one study in BH4-unresponsive PKU patients (Ficicioglu et 
al 2013). This study showed that, after 4 months of BH4 treatment, glucose metabolism in 
left Broca’s and right lateral temporal cortices was increased, which was accompanied by 
enhanced performance in a phonemic fluency test. Ficicioglu et al. hypothesized that this 
could have been the result of BH4-induced vasodilation. As previously mentioned, BH4 
might lead to increased synthesis of NO, dopamine and serotonin. Whilst serotonin has a 
vasoconstrictive effect, dopamine and especially NO have strong vasodilatory qualities. 
Possibly, the increased blood flow enables certain brain regions to compensate for 
imbalances in glucose metabolism. Overall, this hypothesis is only supported by a single 
study in PKU patients (Table 1). Therefore, further research is necessary to establish the 
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effects of BH4 on cerebral energy metabolism, and to investigate whether these effects 
could indeed be beneficial for neurocognitive functioning.  
 
BH4 and white matter 
Finally, some evidence points towards a possible role for BH4 in ameliorating 
neurocognitive functioning in PKU by influencing white matter. White matter 
abnormalities are one of the neuroradiological features characterizing PKU and have been 
observed in both untreated and early-treated (especially if not treated optimally) PKU 
patients (Anderson and Leuzzi 2010). While white matter pathology in untreated PKU is 
generally accepted to reflect hypomyelination, the observed white matter pathology in 
early-treated PKU patients is suggested to reflect intramyelinic edema rather than 
demyelination (Anderson and Leuzzi 2010). The clinical significance of the observed 
white matter abnormalities is still highly debated. However, PKU-related white matter 
abnormalities have been correlated to slowed information processing (Anderson et al 
2004, Anderson et al 2007), which has been found to partly account for the executive 
function impairments seen in PKU (Janos et al 2012).  
A possible relationship between BH4 supplementation and improved myelination has 
been described in BH4 deficiency patients (Wang et al 2006). When comparing their own 
results with a previous study on myelination in BH4 deficiency patients (Chien et al 
2002), Wang et al. (2006) showed more white matter abnormalities. In contrast to these 
differences in neuroradiological findings, age at which dietary treatment was initiated 
was comparable for both patient groups. BH4 as well as neurotransmitter precursor 
treatment (levodopa and 5-HTP), however, was started at later age in the patient group 
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presenting with more white matter abnormalities, suggesting a role for BH4 and 
neurotransmitter precursor treatment in the reversal of white matter pathology (Wang et 
al 2006). More recently, institution of BH4 treatment in early-diagnosed and early-treated 
PKU patients has been shown to improve (and in some cases even fully correct certain 
aspects of) white matter abnormalities, which were significantly associated with 
reductions in blood Phe concentrations (White et al 2013). Whether these clear 
improvements were completely due to the blood Phe lowering effect of BH4 remains to 
be established, as the study was only performed in BH4-responsive PKU patients. In 
addition, neuroimaging findings by functional MRI (fMRI) in early-treated PKU patients 
have shown improved neural activation after 4 weeks of BH4 treatment (20 mg/kg) even 
when blood Phe concentrations had not decreased (Christ et al 2013). Although additional 
research should further elucidate the possible relationship between these deficiencies of 
functional connectivity and white matter abnormalities in PKU, the results obtained by 
fMRI studies are in good agreement with the white matter abnormalities observed in PKU 
(Christ, Moffitt and Peck 2010, Christ et al 2012). Taken together, these results from 
studies in BH4-treated PKU patients hold some promise for BH4 treatment to improve 
neurocognitive functioning in PKU by influencing white matter. The underlying 
mechanism for such possible effect might be multifactorial and is not fully understood.  
 
Conclusion 
Besides lowering blood Phe concentrations in BH4-responsive PKU patients, findings 
suggest that BH4 treatment in PKU may also directly improve neurocognitive 
functioning. While the important question to what extent which peripherally administered 
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doses of BH4 can increase cerebral BH4 concentrations in humans necessitates additional 
investigation, the present review describes the working mechanisms that, theoretically, 
may underlie this possible direct neurocognitive effects of BH4 in PKU. It should be 
emphasized that these hypothesized mechanisms are in large part based on studies in 
animal models and non-PKU-related research, but, taken together, they definitely justify 
further research on this topic. This research should at least focus on 1) further elucidating 
the possible beneficial effects of BH4 treatment on neurocognitive functioning in PKU; 2) 
examining possible negative or toxic effects of BH4 or its metabolites on brain function; 
and 3) the most effective way to increase BH4 concentrations in the brain. Regarding the 
first aim, we suggest that the Pah-enu2 mouse model for BH4-unresponsive PKU could 
be used to identify if, and by which of the described mechanisms, BH4 might improve 
neurocognitive functioning in PKU, beyond its effect through lowering blood Phe 
concentrations. Regarding the second aim, both this mouse model as well as in vitro 
studies could be used to investigate possible toxicity of BH4 at different concentrations, 
especially focusing on the effect of BH4, and the balance between BH4 and BH2, on 
oxidative stress. Thirdly, animal studies should also be used to investigate the optimal 
treatment regimen to increase cerebral BH4 concentrations. This will possibly require 
higher BH4 dosages than currently studied, or, alternatively, treatment with sepiapterin as 
this may be more effective in increasing intracellular BH4 concentrations. Ultimately, the 
effect of BH4 treatment on objective neurocognitive tasks in BH4-unresponsive patients 
should be assessed in a placebo-controlled setting. If BH4 indeed has beneficial 
neurocognitive effects, this may extend the target population of BH4 treatment.  
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Fig 1 A simplified schematic overview of the different hypothesized working 
mechanisms that may underlie a possible direct beneficial effect of BH4 on 
neurocognitive functioning in PKU patients 
 
 
Table 1 An overview of human and non-human studies presenting results that are related 
to the possible neurocognitive effects of tetrahydrobiopterin treatment. 
 
Abbreviations: PKU, phenylketonuria; BH4, tetrahydrobiopterin; BH2, dihydrobiopterin; 
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